Teladoc Health, Inc.
NYSE:TDOCMedical - Healthcare Information Services
+$0.20 today
- Market cap
- $1.47B
- Beta
- 2.14
- P/E (TTM)
- -8.1
- EPS (TTM)
- -$0.96
Volume 3.96M
Average 4.68M
TDOC Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Teladoc Health, Inc.NYSE: TDOC
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $289.81M rose 47.2% year over year, ahead of the +14.7% change in trailing-twelve-month cost of revenue. Sequentially, it rose 47.1% from the prior quarter. Over 3 fiscal years it compounded at +1.2% a year.
Context
- Cost of revenue amounted to 30.5% of revenue in FY2025, up 1.3 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +47.2% holds above the trailing-twelve-month pace of +14.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 771.59M USD
- Year-over-year change
- +2.7%
- 4-year CAGR
- +4.4%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 771.59M | +2.7% |
| FY2024 | 2024-12-31 | 751.27M | -1.2% |
| FY2023 | 2023-12-31 | 760.03M | +2.2% |
| FY2022 | 2022-12-31 | 743.99M | +14.4% |
| FY2021 | 2021-12-31 | 650.26M | — |
Cost of Revenue vs competitors
How TDOC compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +14.7% is the 4th highest of 11, against a peer median of +8.0%.
- Cost of revenue amounts to 34.4% of revenue for TDOC, versus a peer median of 48.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $988.68M USD | +2.5% | +16.7% | 75.4% | |
| LTM Mar 2026 | $864.58M USD | +14.7% | +1.2% | 34.4% | |
| LTM Mar 2026 | $692.19M USD | +7.4% | -1.4% | 56.5% | |
| LTM Mar 2026 | €660.57M EUR | -3.0% | +6.4% | 88.6% | |
| LTM Sep 2026 | $346.74M USD | +8.6% | -7.1% | 55.8% | |
| LTM Apr 2026 | $169.46M USD | +21.9% | +12.1% | 34.2% | |
| LTM Mar 2026 | $167.29M USD | +17.8% | +13.3% | 24.8% | |
| LTM Sep 2026 | $111.68M USD | +3.9% | +12.3% | 41.5% | |
| LTM Mar 2026 | $95.69M USD | +31.6% | +24.4% | 33.8% | |
| LTM Sep 2026 | $753K USD | -98.5% | — | — | |
| LTM Sep 2026 | €106.45K EUR | +9.7% | — | — | |
| Peer median (excluding TDOC) | — | +8.0% | +12.2% | 48.6% | |
Competitors are the stored peer set for TDOC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.03B | 2.41B | 2.6B | 2.57B | 2.53B |
| Cost of Revenue | 650.26M | 743.99M | 760.03M | 751.27M | 771.59M |
| Gross Profit | 1.38B | 1.66B | 1.84B | 1.82B | 1.76B |
| Gross Margin | 68.0% | 69.1% | 70.8% | 70.8% | 69.5% |
| Research & Development | 311.88M | 333.63M | 348.52M | 307.27M | 277.92M |
| Selling, General & Admin | 1.11B | 1.3B | 1.37B | 1.35B | 1.09B |
| Operating Expenses | 1.65B | 15.32B | 2.09B | 2.84B | 2.02B |
| Depreciation & Amortization | 207.57M | 209.93M | 254.11M | 240.51M | 363.12M |
| EBITDA | (31.42M) | (7.54M) | 43.61M | 31.72M | 147.3M |
| EBITDA Margin | -1.5% | -0.3% | 1.7% | 1.2% | 5.8% |
| Operating Income | (265.63M) | (13.65B) | (248.55M) | (1.02B) | (262.96M) |
| Operating Margin | -13.1% | -567.3% | -9.6% | -39.7% | -10.4% |
| Interest Income | 776K | 12.67M | 46.78M | 57.07M | 36.77M |
| Interest Expense | 81.14M | 21.94M | 22.28M | 23.8M | 19.71M |
| Other Income / Expenses | (119.03M) | (10.13M) | 28.95M | 27.23M | 27.43M |
| Income Before Tax | (384.66M) | (13.66B) | (219.61M) | (993.65M) | (235.53M) |
| Pre-Tax Margin | -18.9% | -567.7% | -8.4% | -38.7% | -9.3% |
| Income Tax Expense | 44.14M | (3.81M) | 760K | 7.59M | (35.21M) |
| Net Income | (428.79M) | (13.66B) | (220.37M) | (1B) | (200.32M) |
| Net Margin | -21.1% | -567.5% | -8.5% | -39.0% | -7.9% |
| EPS (Basic) | (2.73) | (84.60) | (1.36) | (5.87) | (1.14) |
| EPS (Diluted) | (2.73) | (84.60) | (1.34) | (5.87) | (1.14) |
| Weighted Avg Shares | 156.94M | 161.46M | 162.17M | 170.56M | 176.22M |
| Weighted Avg Shares (Diluted) | 156.94M | 161.46M | 164.58M | 170.56M | 176.22M |
Teladoc Health, Inc.
NYSE:TDOC
Intrinsic Alpha fair value
Locked
Current Price
$8.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.